Implantable devices need to undergo rigorous biocompatibility assessments before they can be tested in clinical trials. We can save you money by identifying lead candidate biomaterials prior to in vivo testing.
- FDA-required biocompatibility assessments include extensive in vivo testing, which can be both expensive and ethically questionable. Additionally, in vitro and cell culture assays may not be adequately predictive of the in vivo response to biomaterials and devices. Our ex vivo models allow you to bridge the gap between in vitro and in vivo testing by determining human and/or porcine tissue responsiveness to your product.
- Our models are predictive of the in vivo response, allowing you to identify lead candidates and drop cytotoxic/ineffective formulations before they are tested in animals. This will decrease the number of animals needed for in vivo testing and accelerate your project’s transition to the clinical stage.